Multiple Vessel Compression of the Trigeminal Nerve Is Associated With Worse Outcomes in Trigeminal Neuralgia After Microvascular Decompression.

BACKGROUND: Whether the total number of compressive vessels in trigeminal neuralgia (TN) affects outcomes after microvascular decompression (MVD) is unknown. OBJECTIVE: To investigate whether the number of compressive vessels is associated with outcomes after MVD. METHODS: We retrospectively reviewed all patients with TN who underwent MVDs at our institution from 2007 to 2020. The number and identity of compressive vessels on the trigeminal nerve were recorded. Preoperative and postoperative pain and numbness Barrow Neurological Institute scores were compared. Factors associated with pain recurrence were assessed using survival analyses and multivariate regressions. RESULTS: We identified 496 patients with a single vessel and 381 patients with multiple vessels compressing the trigeminal nerve. Compared with patients with a single compressive vessel, patients with multiple sources of compression exhibited increased Barrow Neurological Institute pain scores preoperatively ( P = .01). In addition, pain recurrence was more frequent ( P < .001) and occurred after a significantly shorter pain-free duration ( P < .001) for the multiple compression group. Using multivariate ordinal regression, a greater number of arteries ( P = .03) and veins ( P = .03) were both significantly associated with higher pain scores at final follow-up. Furthermore, the number of arteries ( P = .01) and of veins ( P = .01) was significantly associated with a higher risk for pain recurrence. CONCLUSION: TN patients with a single compressive vessel exhibited better pain outcomes after an MVD. Patients with multiple compressive vessels exhibited higher pain scores preoperatively and incurred a higher risk for pain recurrence, which occurred after a shorter pain-free interval compared with the single compression cohort.

A Novel and Simple Method for stabilizing a Transverse Segment in a Posterior Wall Acetabular Fracture: Continuous Compression Staples, A Report of three Cases.

Introduction: Continuous compression implants (CCI) are a fixation device formed from nitinol, a shape memory alloy. This alloy is durable enough to augment fixation and combined with its small footprint, versatile enough to insert into areas that are too small for K wires or lag screws to hold a provisional fixation. Case Report: We used CCIs to successfully stabilize the transverse segments in three posterior column with posterior wall fractures. Conclusion: CCIs can be used to provisionally reduce posterior column with posterior wall acetabular fractures and stabilize small pelvic bone fragments that may be difficult to hold with lag screws. These cases highlight a novel augmentation of the surgical treatment of posterior column with posterior wall fractures.

Strategies for Glycoengineering Therapeutic Proteins.

Almost all therapeutic proteins are glycosylated, with the carbohydrate component playing a long-established, substantial role in the safety and pharmacokinetic properties of this dominant category of drugs. In the past few years and moving forward, glycosylation is increasingly being implicated in the pharmacodynamics and therapeutic efficacy of therapeutic proteins. This article provides illustrative examples of drugs that have already been improved through glycoengineering including cytokines exemplified by erythropoietin (EPO), enzymes (ectonucleotide pyrophosphatase 1, ENPP1), and IgG antibodies (e.g., afucosylated Gazyva®, Poteligeo®, Fasenra™, and Uplizna®). In the future, the deliberate modification of therapeutic protein glycosylation will become more prevalent as glycoengineering strategies, including sophisticated computer-aided tools for "building in" glycans sites, acceptance of a broad range of production systems with various glycosylation capabilities, and supplementation methods for introducing non-natural metabolites into glycosylation pathways further develop and become more accessible.